drugset
drugset / Trial / NCT02723006

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

NCT02723006 ↗

Phase 1 Terminated 22 enrolled Millennium Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to determine the initial safety profile and initial antitumor activity of the combination treatments (immune checkpoint inhibitors \[nivolumab, ipilimumab\] with investigational drugs \[TAK-580, TAK-202 (plozalizumab), vedolizumab\]) in the 3 arms when administered to participants with advanced melanoma.

Timeline

Start
2016-06-22
Primary completion
2018-05-11
Completion
2018-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PLOZALIZUMAB Monoclonal antibody 2 mg Intravenous
Subject Tovorafenib Small molecule — Oral
Subject Vedolizumab Monoclonal antibody — Intravenous
Background Ipilimumab Monoclonal antibody — Intravenous
Background Nivolumab Monoclonal antibody — Intravenous

Indications

melanoma